Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP
Executive Summary
Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.
You may also be interested in...
Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity
New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
With Strong Q3 Financials, Pfizer Says It's Ready For Generic Competition To Lipitor
The world's largest pharma highlights sales growth of Prevnar 13, Enbrel and Lyrica, emerging markets growth, and a developing plan to sell off animal health and nutritional units.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: